{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:16:41Z","timestamp":1777457801084,"version":"3.51.4"},"reference-count":28,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2008,8,1]],"date-time":"2008-08-01T00:00:00Z","timestamp":1217548800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2008,9]]},"abstract":"<jats:p><jats:bold>Summary.\u2002<\/jats:bold>von Willebrand factor (VWF) is a multimeric glycoprotein that mediates platelet adhesion and is decreased in von Willebrand disease (VWD). 1\u20108 deamino\u2010<jats:sc>d\u2010<\/jats:sc>arginine vasopressin (DDAVP), the most common treatment for VWD, is limited by tachyphylaxis and inconvenience, and in 20% of the patients, unresponsiveness. Recombinant human interleukin\u201011 (rhIL\u201011), a gp\u2010130 signalling cytokine with haematopoietic and anti\u2010inflammatory activity, increases VWF antigen and its activity in heterozygous VWF<jats:sup>+\/\u2212<\/jats:sup>mice and dogs. To determine the biological efficacy and safety of rhIL\u201011 in non\u2010bleeding human subjects with mild VWD, we conducted a phase II prospective open\u2010label trial of rhIL\u201011 at 10, 25 and 50\u2003\u03bcg\u2003kg<jats:sup>\u22121<\/jats:sup>subcutaneously (s.c.), given daily for 7\u2003days in nine subjects with mild VWD. VWF and factor VIII (FVIII) levels increased gradually and progressively after s.c. rhIL\u201011, which was sustained through 7\u2003days of dosing to 1.5\u2010 to 3\u2010fold over baseline. Following intravenous DDAVP, 0.3\u2003\u03bcg\u2003kg<jats:sup>\u22121<\/jats:sup>, on day 7 there was a further boost in VWF and FVIII levels, suggesting that the mechanism of rhIL\u201011 differs from that of DDAVP. Platelet VWF mRNA expression measured by quantitative PCR increased from two\u2010 to eightfold over baseline, suggesting that the mechanism of rhIL\u201011 effect may be upregulation of VWF mRNA. VWF and FVIII levels returned to baseline by day 14. rhIL\u201011 was well tolerated with less than grade\u20101 hypertension, hypokalaemia and fluid retention. Recombinant IL\u201011 increases VWF levels in humans with mild VWD, justifying future clinical trials to determine its potential in preventing or reducing bleeding in this patient population.<\/jats:p>","DOI":"10.1111\/j.1365-2516.2008.01827.x","type":"journal-article","created":{"date-parts":[[2008,8,1]],"date-time":"2008-08-01T09:16:27Z","timestamp":1217582187000},"page":"968-977","source":"Crossref","is-referenced-by-count":23,"title":["A phase II prospective open\u2010label escalating dose trial of recombinant interleukin\u201011 in mild von Willebrand disease"],"prefix":"10.1111","volume":"14","author":[{"given":"M. V.","family":"RAGNI","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. C.","family":"JANKOWITZ","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. L.","family":"CHAPMAN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. P.","family":"MERRICKS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. T.","family":"KLOOS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. M.","family":"DILLOW","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. C.","family":"NICHOLS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,8,28]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1651576"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.02146.x"},{"key":"e_1_2_7_4_2","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1182\/blood.V69.2.454.454","article-title":"Epidemiologic investigation of the prevalence of Von Willebrand disease","volume":"69","author":"Rodeghiro F","year":"1987","journal-title":"Blood"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1613992"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1999.00342.x"},{"key":"e_1_2_7_7_2","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1182\/blood.V90.7.2515","article-title":"Desmopressin in the treatment of bleeding disorders: the first 20\u2003years","volume":"90","author":"Mannucci PM","year":"1997","journal-title":"Blood"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01663.x"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp068178"},{"key":"e_1_2_7_10_2","first-page":"3","volume-title":"Medical Product Safety","author":"Healthy People","year":"2010"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01643.x"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.11.3368"},{"key":"e_1_2_7_13_2","first-page":"3435","volume-title":"Neumega: product information","author":"Physician's Desk Reference","year":"2007"},{"key":"e_1_2_7_14_2","first-page":"278a","article-title":"Recombinant human interleukin eleven (Neumega, rhIL\u201011 growth factor) increases plasma von Willebrand factor and fibrinogen concentrations in normal human subjects","volume":"84","author":"Kaye J","year":"1994","journal-title":"Blood"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.2.465"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0290"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-021105."},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-020784"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-02-0464"},{"key":"e_1_2_7_20_2","first-page":"420","article-title":"A multispecies enzyme\u2010linked immunosorbent assay for von Willebrand\u2019s factor","volume":"119","author":"Benson RE","year":"1992","journal-title":"J Lab Clin Med"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.19.12.3055"},{"key":"e_1_2_7_22_2","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1182\/blood.V81.10.2644.2644","article-title":"The roles of von Willebrand factor and factorVIII in arterial thrombosis: studies in canine von Willebrand disease and hemophilia A","volume":"81","author":"Nichols TC","year":"1993","journal-title":"Blood"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2937"},{"key":"e_1_2_7_24_2","unstructured":"Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events version 3.0 DCTD NCI NIH DHHS 2003. Available at:http:\/\/ctep.cancer.gov."},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1538-7836.2003.00190.x"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01553.x"},{"key":"e_1_2_7_27_2","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0022-3565(24)36848-X","article-title":"V2 receptors antagonism of DDAVP\u2010induced release of hemostasis factors in conscious dogs","volume":"282","author":"Bernat A","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI9516"},{"key":"e_1_2_7_29_2","first-page":"2689","article-title":"Interactions between von Willebrand factor and factor VIII: where did they first meet?","volume":"20","author":"Montgomery RR","year":"2000","journal-title":"J Pediatr Hematol Oncol"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2516.2008.01827.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2516.2008.01827.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T08:11:06Z","timestamp":1738311066000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2516.2008.01827.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8,28]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["10.1111\/j.1365-2516.2008.01827.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2516.2008.01827.x","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8,28]]}}}